An easy growing international specialist in Molecular Nuclear Medication.

The acquisition gives AAA its first direct presence in the united kingdom and Ireland, expanding its existing experience and companies in nuclear medicine and providing this with a recognised sales and marketing platform. AAA will also gain the privileges in the UK and Ireland to IEL's licensed SPECT radiopharmaceutical diagnostic product, IELMAG3, which is used to image the kidneys and urinary system.77 million, up 58 percent on the prior year. Related StoriesInnovative mini hybrid gamma ray video camera enhances removal of tumours and lymph nodesNew Christian Doppler Laboratory for Clinical Molecular MR Imaging opens at MedUni ViennaMallinckrodt subsidiary to acquire Therakos for $1. IEL's expert expertise and strong presence in these markets is a complementary match AAA's business and we anticipate working with their management team to operate a vehicle the integration and growth in 2014.’ Founded in 2001, IEL is an expert distributor of medical technology in the united kingdom and Ireland.AMAG estimates approximately 70 percent of Feraheme provider demand in the next one fourth of 2010 was outside of the dialysis setting, with hospitals and hematology clinics representing nearly all this demand. From launch through the end of the next quarter of 2010, approximately 2,300 suppliers have purchased Feraheme, with greater than 73 percent having bought on a do it again basis. In the second quarter of 2010, more than 620 companies bought Feraheme for the very first time; 68 percent of the new customers were hematology clinics and hospitals. ‘In the near term, we are focused on the successful commercialization of Feraheme in the CKD market and are pleased with the continued development in Feraheme utilization,’ stated Brian J.G.